Want to see HK:1951 full AI Analyst Report?
1951 Stock Chart & Stats
HK$2.27
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.92 - HK$2.67
Previous CloseN/A
Volume3.76M
Average Volume (3M)8.94M
Market Cap
HK$6.07B
Enterprise ValueHK$7.83B
Total Cash (Recent Filing)HK$804.61M
Total Debt (Recent Filing)HK$3.00B
Price to Earnings (P/E)26.6
Beta0.67
Next Earnings
Mar 31, 2027EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield1.85%
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,705,044,000
10 Day Avg. Volume8,651,420
30 Day Avg. Volume8,936,994
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.35Price Target Upside47.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.85B
Bulls Say, Bears Say
Bulls Say
Manageable LeverageManageable leverage and substantial equity provide Jinxin Fertility with balance-sheet flexibility as it operates through changing demand and profitability. Lower financial strain can preserve capacity to fund clinical operations, maintain services, and pursue growth without excessive dependence on borrowing.
Positive Operating Cash FlowContinued positive operating cash flow indicates that the core fertility-services business is still converting activity into cash despite the 2025 earnings deterioration. This supports ongoing operations and gives the company an internal funding source, reducing immediate reliance on external capital.
Underlying Operating ProfitabilityPositive EBIT and EBITDA margins show that the operating platform retained underlying profitability even as reported net income turned sharply negative. This residual operating economics may provide a base for recovery if revenue stabilizes and the factors below the operating line improve.
Bears Say
Revenue ContractionA revenue decline after stronger expansion in 2021–2022 signals weakening momentum in the company’s fertility-services activity. Prolonged contraction would reduce operating leverage, make fixed clinical costs harder to absorb, and constrain the resources available for investment and expansion.
Sharp Net LossThe swing from solid prior-year net margins to a substantial 2025 loss materially weakens earnings quality and shareholder returns. Unless profitability recovers, the loss can limit reinvestment capacity, reduce financial resilience, and make future performance more dependent on operational improvement.
Declining Free Cash FlowThe sharp free-cash-flow decline reduces financial flexibility even though operating cash flow remained positive. Less internally generated cash can constrain spending on facilities, clinical capabilities, and other growth needs, while also leaving a smaller buffer against continued earnings weakness.
Jinxin Fertility Group Ltd. News
1951 FAQ
What was Jinxin Fertility Group Ltd.’s price range in the past 12 months?
Jinxin Fertility Group Ltd. lowest stock price was HK$1.92 and its highest was HK$2.67 in the past 12 months.
What is Jinxin Fertility Group Ltd.’s market cap?
Jinxin Fertility Group Ltd.’s market cap is HK$6.07B.
When is Jinxin Fertility Group Ltd.’s upcoming earnings report date?
Jinxin Fertility Group Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 152 days.
How were Jinxin Fertility Group Ltd.’s earnings last quarter?
Jinxin Fertility Group Ltd. released its earnings results on Aug 21, 2026. The company reported HK$0.047 earnings per share for the quarter, beating the consensus estimate of HK$0.035 by HK$0.012.
Is Jinxin Fertility Group Ltd. overvalued?
According to Wall Street analysts Jinxin Fertility Group Ltd.’s price is currently Undervalued.
Does Jinxin Fertility Group Ltd. pay dividends?
Jinxin Fertility Group Ltd. pays a Notavailable dividend of HK$0.042 which represents an annual dividend yield of 1.85%. See more information on Jinxin Fertility Group Ltd. dividends here
What is Jinxin Fertility Group Ltd.’s EPS estimate?
Jinxin Fertility Group Ltd.’s EPS estimate is 0.04.
How many shares outstanding does Jinxin Fertility Group Ltd. have?
Jinxin Fertility Group Ltd. has 2,705,044,000 shares outstanding.
What happened to Jinxin Fertility Group Ltd.’s price movement after its last earnings report?
Jinxin Fertility Group Ltd. reported an EPS of HK$0.047 in its last earnings report, beating expectations of HK$0.035. Following the earnings report the stock price went up 3.963%.
Which hedge fund is a major shareholder of Jinxin Fertility Group Ltd.?
Currently, no hedge funds are holding shares in HK:1951
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jinxin Fertility Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.46%
12-Months-Change
Fundamentals
Return on Equity
1.87%
Trailing 12-Months
Asset Growth
4.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial insemination, which can be performed using either the husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies, ranging from conventional IVF with embryo transfer to IVF utilizing intracytoplasmic sperm injection (ICSI). To complement its ARS treatments, the company also furnishes a range of supportive services such as nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Beyond fertility-specific care, Jinxin Fertility Group extends its operations to include management services, general medical care encompassing gynecology, urology, and internal medicine, as well as ambulatory surgery center facilities and other ancillary medical services. Furthermore, the company conducts pre-implantation genetic screening tests. Its business scope also diversifies into investment management, management consulting, and real estate development and operation. Jinxin Fertility Group Limited was established in 2003 and has its corporate headquarters located in Chengdu, China.
1951 Stock 12 Month Forecast
Average Price Target
HK$3.35
▲(47.58% Upside)
Technical Analysis
―
Kindstar Globalgene Technology, Inc.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Concord Healthcare Group Co., Ltd. Class H
―